NEWTON - Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a biopharmaceutical company in the clinical stage, announced today its plans to present new data from its Phase 2 ALTITUDE-AD clinical trial for early Alzheimer's disease at an upcoming conference. The presentation will focus on the company's use of a plasma pTau217 assay as a screening tool for trial participants.
The late-breaking presentation, scheduled for next Thursday in Madrid, Spain, will detail the application of the assay in identifying individuals with Alzheimer's pathology for inclusion in the ALTITUDE-AD study. This assay detects phosphorylated tau at position 217, a biomarker for Alzheimer's disease, and serves as an initial screening step before further amyloid testing.
Sabirnetug (ACU193), the investigational therapeutic being evaluated in the ALTITUDE-AD trial, is a humanized monoclonal antibody targeting soluble amyloid beta oligomers (AβOs). These oligomers are considered to be neurotoxic and implicated in the neurodegeneration associated with Alzheimer's. Sabirnetug has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of early Alzheimer's disease.
The ALTITUDE-AD trial, which began in 2024, is a randomized, double-blind, placebo-controlled study designed to assess whether sabirnetug can slow cognitive and functional decline in early Alzheimer's disease patients. The trial aims to enroll approximately 540 individuals with mild cognitive impairment or mild dementia due to Alzheimer's across several countries, including the United States, Canada, the UK, and the European Union.
This update on Acumen's screening approach for the ALTITUDE-AD trial is based on a press release statement and will be part of the 17th Annual Clinical Trials on Alzheimer's Disease conference. The presentation will take place at the Madrid Marriott Auditorium Hotel and Conference Center, with Senior Clinical Research Scientist Todd Feaster, Psy.D., representing Acumen Pharmaceuticals. Further information about the trial can be found on the ClinicalTrials.gov website under the identifier NCT06335173.
In other recent news, Acumen Pharmaceuticals has been making significant strides in its clinical trials and financial status. The company's Alzheimer's drug candidate, sabirnetug, is currently undergoing a Phase 2 study, ALTITUDE-AD, with enrollment progressing well and completion expected in 2025. Acumen has also initiated a Phase 1 study for a subcutaneous version of sabirnetug, aiming to increase dosing flexibility.
Financially, Acumen holds a strong position, with $281 million in cash and marketable securities, expecting its funds to last until the first half of 2027. The company has also expanded its partnership with Lonza, a global manufacturing partner, to prepare for the potential commercial launch of sabirnetug.
Analyst firms Stifel, H.C. Wainwright, and BTIG have maintained their Buy ratings on Acumen, reflecting confidence in the potential of sabirnetug. Stifel and H.C. Wainwright have set their price targets at $10 and $15 respectively, while BTIG has set its price target at $11. These recent developments highlight Acumen Pharmaceuticals' ongoing efforts to advance its Alzheimer's disease treatment candidate through clinical trials and prepare for possible commercial distribution.
InvestingPro Insights
As Acumen Pharmaceuticals (NASDAQ:ABOS) prepares to present new data from its Phase 2 ALTITUDE-AD clinical trial, investors may find additional context from InvestingPro's financial metrics and tips valuable.
According to InvestingPro data, Acumen's market capitalization stands at $168.22 million, reflecting the market's current valuation of the company's potential in the Alzheimer's treatment space. The company's price-to-book ratio of 0.69 suggests that the stock may be undervalued relative to its book value, which could be of interest to value-oriented investors considering the company's clinical-stage assets.
InvestingPro Tips highlight that Acumen holds more cash than debt on its balance sheet, which is crucial for a clinical-stage biopharmaceutical company as it provides financial flexibility to fund ongoing research and development efforts, including the ALTITUDE-AD trial. However, the company is also quickly burning through cash, a common characteristic of pre-revenue biotech firms investing heavily in clinical trials.
The stock has shown a significant return over the last week and a strong return over the last month, with 17.15% and 18.14% gains respectively, possibly reflecting investor optimism about the upcoming data presentation. Despite these recent gains, InvestingPro Tips indicate that analysts do not anticipate the company will be profitable this year, which is not unusual for companies at this stage of drug development.
For investors seeking a more comprehensive analysis, InvestingPro offers 9 additional tips for Acumen Pharmaceuticals, providing a deeper understanding of the company's financial health and market position as it advances its Alzheimer's disease candidate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.